Overview
- AstraZeneca said its antibody tozorakimab reduced moderate-to-severe COPD flare-ups versus placebo in two late-stage studies.
- The replicate OBERON and TITANIA trials enrolled 2,306 patients and tested a 300 mg dose every four weeks on top of inhaled therapy for 52 weeks.
- Benefits were seen in the main group of former smokers and in the overall study population, and the drug was generally well tolerated.
- The antibody targets interleukin‑33 to dampen airway inflammation and thick mucus, processes that often trigger COPD worsening.
- AstraZeneca shares rose about 4% after the update, and additional Phase 3 results expected in the first half of 2026 will further clarify the outlook.